Grants and Contributions:
Title:
UK Biomanufacturing - 10141267 - BPE Human Vaccines - Implementation of High Yielding Plasmid DNA Platform for Human Vaccine Manufacturing
Agreement Number:
1028954
Agreement Value:
$514,123.00
Agreement Date:
Apr 1, 2025 - Mar 30, 2027
Description:
This project leverages the combined vaccine development platform technologies of Pegasus Biotech, ConserV Bio and 4BaseBio to evaluate and enhance the manufacturing capability of a novel Canadian plasmid DNA technology platform (BPE) in the production of a new class of human influenza vaccines based on ConserV Bio's FLU-v technology.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Charlottetown, Prince Edward Island, CA C1A 4P3
Reference Number:
172-2025-2026-Q1-1028954
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
760829879
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 25,000 dollars.
Amendment Date
Jan 28, 2026
Recipient's Legal Name:
Pegasus Biotech Incorporated
Federal Riding Name:
Charlottetown
Federal Riding Number:
11002
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
541710
Amendments: